Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Geenen JJJ"'
Autor:
Moore KN; Sarah Cannon Research Institute, Nashville, Tennessee. Kathleen-Moore@ouhsc.edu.; Stephenson Cancer Center at the University of Oklahoma HSC, Oklahoma City, Oklahoma., Chambers SK; The University of Arizona Cancer Center, Tucson, Arizona., Hamilton EP; Sarah Cannon Research Institute, Nashville, Tennessee.; Tennessee Oncology, PLLC, Nashville, Tennessee., Chen LM; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California., Oza AM; Bras Drug Development Program, Princess Margaret Cancer Centre, Toronto, Canada., Ghamande SA; Augusta University, Augusta, Georgia., Konecny GE; UCLA, Los Angeles, California., Plaxe SC; UC San Diego Health, La Jolla, California., Spitz DL; Sarah Cannon Research Institute, Nashville, Tennessee.; Florida Cancer Specialists & Research Institute, Wellington, Florida., Geenen JJJ; Netherlands Cancer Institute, Amsterdam, the Netherlands., Troso-Sandoval TA; Memorial Sloan Kettering Cancer Center, New York, New York., Cragun JM; The University of Arizona Cancer Center, Tucson, Arizona., Rodrigo Imedio E; Oncology Global Medicines Development (GMD), AstraZeneca, Cambridge, United Kingdom., Kumar S; Oncology Global Medicines Development (GMD), AstraZeneca, Cambridge, United Kingdom., Mugundu GM; Quantitative Clinical Pharmacology, Early Clinical Development, IMED Biotech Unit, AstraZeneca, Boston, Massachusetts., Lai Z; Translational Medicine, Oncology Research and Development, AstraZeneca, Boston, Massachusetts., Chmielecki J; Translational Medicine, Oncology Research and Development, AstraZeneca, Boston, Massachusetts., Jones SF; Sarah Cannon Research Institute, Nashville, Tennessee., Spigel DR; Sarah Cannon Research Institute, Nashville, Tennessee.; Tennessee Oncology, PLLC, Nashville, Tennessee., Cadoo KA; Memorial Sloan Kettering Cancer Center, New York, New York.; Weill Cornell Medical College, New York, New York.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2022 Jan 01; Vol. 28 (1), pp. 36-44. Date of Electronic Publication: 2021 Oct 13.
Autor:
Geenen JJJ; Department of Clinical Pharmacology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Division of Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Dackus GMHE; Department of Molecular Pathology, Antoni van Leeuwenhoek Hospital - Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Pathology, Utrecht University Medical Center, Utrecht, The Netherlands., Schouten PC; Department of Molecular Pathology, Antoni van Leeuwenhoek Hospital - Netherlands Cancer Institute, Amsterdam, The Netherlands., Pluim D; Division of Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Marchetti S; Division of Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Medical Oncology, Antoni van Leeuwenhoek Hospital - Netherlands Cancer Institute, Amsterdam, The Netherlands., Sonke GS; Department of Medical Oncology, Antoni van Leeuwenhoek Hospital - Netherlands Cancer Institute, Amsterdam, The Netherlands., Jóźwiak K; Brandenburg Medical School Theodor Fontane, Institute of Biostatistics and Registry Research, Neuruppin, Germany., Huitema ADR; Department of Clinical Pharmacology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Clinical Pharmacy, Utrecht University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.; Faculty of Science, Utrecht Institute of Pharmaceutical Sciences (UIPS), Utrecht, The Netherlands., Beijnen JH; Department of Clinical Pharmacology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Clinical Pharmacy, Utrecht University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.; Faculty of Science, Utrecht Institute of Pharmaceutical Sciences (UIPS), Utrecht, The Netherlands., Schellens JHM; Faculty of Science, Utrecht Institute of Pharmaceutical Sciences (UIPS), Utrecht, The Netherlands., Linn SC; Department of Molecular Pathology, Antoni van Leeuwenhoek Hospital - Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Pathology, Utrecht University Medical Center, Utrecht, The Netherlands.; Department of Medical Oncology, Antoni van Leeuwenhoek Hospital - Netherlands Cancer Institute, Amsterdam, The Netherlands.
Publikováno v:
International journal of cancer [Int J Cancer] 2021 Jun 15; Vol. 148 (12), pp. 3041-3050. Date of Electronic Publication: 2021 Feb 27.
Autor:
Geenen JJJ; Department of Clinical Pharmacology, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, 1066 CX, The Netherlands.; Division of Pharmacology, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, 1066 CX, The Netherlands., Linn SC; Department of Molecular Pathology, Antoni van Leeuwenhoek Hospital, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.; Division of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.; Department of Pathology, Utrecht University Medical Center, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands., Beijnen JH; Department of Clinical Pharmacology, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, 1066 CX, The Netherlands.; Division of Pharmacology, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, 1066 CX, The Netherlands.; Department of Pharmacy, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, 1066 CX, The Netherlands.; Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, The Netherlands., Schellens JHM; Department of Clinical Pharmacology, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, 1066 CX, The Netherlands. j.schellens@nki.nl.; Division of Pharmacology, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, 1066 CX, The Netherlands. j.schellens@nki.nl.; Division of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands. j.schellens@nki.nl.; Department of Pharmacy, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, 1066 CX, The Netherlands. j.schellens@nki.nl.; Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, The Netherlands. j.schellens@nki.nl.
Publikováno v:
Clinical pharmacokinetics [Clin Pharmacokinet] 2018 Apr; Vol. 57 (4), pp. 427-437.
Autor:
Geenen JJJ; Department of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Schellens JHM; Department of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands. j.schellens@nki.nl.; Department of Clinical Pharmacology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Division of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, the Netherlands.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2017 Aug 15; Vol. 23 (16), pp. 4540-4544. Date of Electronic Publication: 2017 Apr 25.